TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15983180

Group type: COMPARATOR
Intervention: Light physical activity
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Moderate-high physical activity
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Light physical activity (women)
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Moderate-high physical activity (women)
Number of subjects: 1004
Study: 12463730

Group type: EXPERIMENTAL
Intervention: rosuvastatin (40 mg once daily)
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study: 10367540

Group type: EXPERIMENTAL
Intervention: Gemcitabine (1.000/1.250 mg/m2, administered on days 1, 8, 15 every 4 weeks)
Number of subjects: 18
Study: 7478688

Group type: EXPERIMENTAL
Intervention: Citalopram 20 mg/day for 4 weeks, increased to 40 mg if no marked improvement after 4 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 2110198

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium (200 mg orally four times per day)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium
Number of subjects: 11
Study: 6108175

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 18

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 18
Study: 31761854

Group type: EXPERIMENTAL
Intervention: Facial rehabilitation exercise (60 minutes once a week for 12 weeks)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Facial rehabilitation exercise
Number of subjects: 21

Group type: COMPARATOR
Intervention: Non-intervention group
Number of subjects: 21
Study: 29075862

Group type: EXPERIMENTAL
Intervention: External pneumatic compression (EPC)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 18
Study: 27018464

Group type: EXPERIMENTAL
Intervention: Simultaneous use of oxytocin and Foley balloon
Number of subjects: 166

Group type: COMPARATOR
Intervention: Sequential use of Foley balloon followed by oxytocin
Number of subjects: 166
Study: 24946565

Group type: EXPERIMENTAL
Intervention: Tripterygium glycosides (20 mg, three times a day for three months)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Prednisone (0.75 mg kg-1 d-1, gradually reduced to 5 mg d-1)
Number of subjects: 64
Study: 23297561

Group type: EXPERIMENTAL
Intervention: Innovative Tuina manipulations
Number of subjects: 126

Group type: COMPARATOR
Intervention: Routine Tuina manipulations (Control)
Number of subjects: 126
Study: 20376462

Group type: EXPERIMENTAL
Intervention: Riboflavin-UVA-induced corneal collagen cross-linking (CXL)
Number of subjects: 127
Study: 18657280

Group type: EXPERIMENTAL
Intervention: Lekker Fit! intervention including professional physical education teacher, three PE classes per week, additional sport and play activities, fitness testing, classroom education on nutrition and active living, and parental involvement.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no intervention implemented).
Number of subjects: 20
Study: 15813763

Group type: EXPERIMENTAL
Intervention: Weekly Browsing Journal Club (WBJC)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Health news website (control)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Both groups (WBJC and control)
Number of subjects: 107
Study: 12815309

Group type: EXPERIMENTAL
Intervention: 65%/65% tilt
Number of subjects: 57

Group type: COMPARATOR
Intervention: 42%/42% tilt
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: System impedance for Group 1
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: System impedance for Group 2
Number of subjects: 57
Study: 10601505

Group type: EXPERIMENTAL
Intervention: Efavirenz (600 mg daily) plus zidovudine (300 mg twice daily) and lamivudine (150 mg twice daily)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Indinavir (800 mg every eight hours) plus zidovudine and lamivudine
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Efavirenz plus indinavir (1000 mg every eight hours)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Indinavir plus zidovudine and lamivudine
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: All combinations
Number of subjects: 450

Group type: COMPARATOR
Intervention: Indinavir and two nucleoside reverse‐transcriptase inhibitors
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Efavirenz and two nucleoside reverse‐transcriptase inhibitors
Number of subjects: 450
Study: 8720308

Group type: EXPERIMENTAL
Intervention: Lumbricus spencer, single oral dose of 500 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lumbricus spencer, 1500 mg/d for one week
Number of subjects: 0
Study: 8384953

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3698511

Group type: EXPERIMENTAL
Intervention: Adrenaline infusion at incremental rates (4, 10, 25, and 62.5 ng min‐1 kg‐1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Noradrenaline infusion
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control infusion
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Adrenaline infusion at highest rate
Number of subjects: 6
Study: 29363115

Group type: EXPERIMENTAL
Intervention: Before the 2011 terrorist attacks in Norway
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: After the 2011 terrorist attacks in Norway
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of both experiments
Number of subjects: 0
Study: 29724537

Group type: EXPERIMENTAL
Intervention: Cosmetically modified brace (labeled as a prototype computerized brace)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Identical brace (not labeled as computerized)
Number of subjects: 18
Study: 27150080

Group type: EXPERIMENTAL
Intervention: Methylphenidate (20 mg oral)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 24332933

Group type: EXPERIMENTAL
Intervention: Nonverbally involved error disclosure (video vignette)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Nonverbally uninvolved error disclosure (video vignette)
Number of subjects: 216
Study: 24666893

Group type: EXPERIMENTAL
Intervention: Basic root canal treatment (BRT) with tactile working length determination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard endodontic treatment with radiographic working length control
Number of subjects: 0
Study: 22563844

Group type: EXPERIMENTAL
Intervention: Preference of mathematics training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized assignment to treatment
Number of subjects: 0
Study: 19651669

Group type: EXPERIMENTAL
Intervention: Arm-ergometry
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Treadmill walking
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Combination (arm-ergometry + treadmill)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control
Number of subjects: 41
Study: 17853009

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day for 1 month
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 15077098

Group type: EXPERIMENTAL
Intervention: Clopidogrel and aspirin
Number of subjects: 307

Group type: COMPARATOR
Intervention: Ticlopidine and aspirin
Number of subjects: 307
Study: 12623509

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg/day for 12 months
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no losartan)
Number of subjects: 16
Study: 9656856

Group type: EXPERIMENTAL
Intervention: Iatrosedative interview
Number of subjects: 58

Group type: COMPARATOR
Intervention: Standard interview
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Iatrosedative interview with same dentist
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Iatrosedative interview with different dentist
Number of subjects: 58
Study: 8608285

Group type: EXPERIMENTAL
Intervention: Diuretic
Number of subjects: 2584

Group type: EXPERIMENTAL
Intervention: Beta blocker
Number of subjects: 2584

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2584
Study: 1748138

Group type: EXPERIMENTAL
Intervention: 0.25 mg hCT
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.5 mg hCT
Number of subjects: 30

Group type: COMPARATOR
Intervention: 100 IU sCT
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: hCT and sCT
Number of subjects: 30

Group type: COMPARATOR
Intervention: sCT
Number of subjects: 30
Study: 6763404

Group type: EXPERIMENTAL
Intervention: Antihypertensive pharmacotherapy
Number of subjects: 10

Group type: COMPARATOR
Intervention: Homeopathic treatment
Number of subjects: 10
Study: 29067880

Group type: EXPERIMENTAL
Intervention: Loving kindness meditation (LKM) with anodal tDCS applied to right TPJ
Number of subjects: 87

Group type: COMPARATOR
Intervention: Relaxation control recording with anodal tDCS
Number of subjects: 87
Study: 27707789

Group type: EXPERIMENTAL
Intervention: TSO 250
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: TSO 2500
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: TSO 7500
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study: 24807084

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) 130/0.42
Number of subjects: 804

Group type: COMPARATOR
Intervention: Ringer's acetate
Number of subjects: 804
Study: 21331467

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Acetaminophen/paracetamol
Number of subjects: 481

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 481
Study: 19322096

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simvastatin 20-40 mg
Number of subjects: 0
Study: 20208238

Group type: EXPERIMENTAL
Intervention: Core Training on guidelines and procedures, didactic diabetes self‐management education, and research protocol training
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Supplemental training utilizing participatory methods
Number of subjects: 542
Study: 15301218

Group type: EXPERIMENTAL
Intervention: Novel oral water irrigator
Number of subjects: 35

Group type: COMPARATOR
Intervention: Conventional electric toothbrush
Number of subjects: 35
Study: 11275936

Group type: EXPERIMENTAL
Intervention: Genetic polymorphisms of the renin-angiotensin-aldosterone system (RAAS) including ACE, AGTR1, AGT, CMA, CYP11B2
Number of subjects: 105
Study: 9789474

Group type: EXPERIMENTAL
Intervention: Inhaled steroids
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Cortisone
Number of subjects: 2
Study: 8014724

Group type: EXPERIMENTAL
Intervention: Stratified life-expectancy data
Number of subjects: 330

Group type: COMPARATOR
Intervention: Averaged life-expectancy data
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Cost increase (tenfold)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Cost-effectiveness criteria
Number of subjects: 330
Study: 1809419

Group type: EXPERIMENTAL
Intervention: Hypnotically recalled anger
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hypnotically recalled fear
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hypnotically recalled depression
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hypnotically recalled happy
Number of subjects: 12

Group type: COMPARATOR
Intervention: Neutral hypnotic control condition
Number of subjects: 12

Group type: COMPARATOR
Intervention: Posthypnotic awake control condition
Number of subjects: 12

Group type: COMPARATOR
Intervention: Prehypnotic baseline condition
Number of subjects: 12
Study: 6218097

Group type: EXPERIMENTAL
Intervention: mezlocillin (4 g 6-hourly)
Number of subjects: 80

Group type: COMPARATOR
Intervention: carbenicillin (5 g 4-hourly)
Number of subjects: 80
Study: 30660371

Group type: EXPERIMENTAL
Intervention: Inhalation of lavender oil
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no lavender oil)
Number of subjects: 80
Study: 28930494

Group type: EXPERIMENTAL
Intervention: Momelotinib 200 mg once daily
Number of subjects: 432

Group type: COMPARATOR
Intervention: Ruxolitinib 20 mg twice a day
Number of subjects: 432
Study: 27538757

Group type: EXPERIMENTAL
Intervention: PREPARE (physiotherapeutic prehabilitation program based on a cognitive behavioural approach)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: PREPARE (physiotherapeutic prehabilitation program)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 110
Study: 23838316

Group type: EXPERIMENTAL
Intervention: OCDC vaccine (dendritic cells pulsed with HOCl-oxidized autologous tumor lysate)
Number of subjects: 5
Study: 21219979

Group type: EXPERIMENTAL
Intervention: Pandemic (H1N1) 2009 vaccine containing 7.5 μg of hemagglutinin (HA)
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Pandemic (H1N1) 2009 vaccine containing 15 μg of hemagglutinin (HA)
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Second dose of A H1N1 vaccine
Number of subjects: 474

Group type: COMPARATOR
Intervention: Pandemic (H1N1) 2009 vaccine formulations
Number of subjects: 474
Study: 19809382

Group type: EXPERIMENTAL
Intervention: Postchemotherapy tumor gene signatures (T2)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Chemotherapy-induced relative change signatures (TDelta)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Baseline tumor gene signatures (T1)
Number of subjects: 47
Study: 17325142

Group type: EXPERIMENTAL
Intervention: 1% atropine drops
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: 1% cyclopentolate and 0.5% tropicamide
Number of subjects: 233

Group type: COMPARATOR
Intervention: 1% cyclopentolate
Number of subjects: 233
Study: 14769568

Group type: EXPERIMENTAL
Intervention: Behavioral intervention designed to improve compliance with evidenced-based guidelines of central venous catheter management.
Number of subjects: 4489

Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 4489
Study: 12324295

Group type: EXPERIMENTAL
Intervention: Flour fortified with iron only (60 mg Fe/kg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Flour cofortified with zinc sulfate (60 mg Zn/kg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Flour cofortified with zinc oxide (60 mg Zn/kg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Zinc sulfate cofortified flour
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Zinc oxide cofortified flour
Number of subjects: 90
Study: 9880768

Group type: EXPERIMENTAL
Intervention: Combined modality therapy with radioisotope implantation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intraoperative radiation therapy (IORT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New chemotherapeutic agents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postoperative adjuvant therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: More aggressive regimens
Number of subjects: 0
Study: 7976093

Group type: EXPERIMENTAL
Intervention: Calcipotriol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Clobetasol propionate 0.05%
Number of subjects: 24
Study: 3384245

Group type: EXPERIMENTAL
Intervention: DVI mode
Number of subjects: 23

Group type: COMPARATOR
Intervention: VVI mode
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: DVI mode (Group A)
Number of subjects: 23

Group type: COMPARATOR
Intervention: VVI mode (Group A)
Number of subjects: 23
Study: 31194613

Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg/d (neoadjuvant therapy for 42 days; adjuvant therapy for up to 12 months)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Gemcitabine 1,250 mg/m2 plus cisplatin 75 mg/m2 (neoadjuvant therapy for two cycles; adjuvant therapy for up to two cycles)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 72

Group type: COMPARATOR
Intervention: Gemcitabine plus cisplatin
Number of subjects: 72
Study: 28286331

Group type: EXPERIMENTAL
Intervention: Patient direct access to physiotherapy pathway
Number of subjects: 978

Group type: COMPARATOR
Intervention: Usual GP-led care
Number of subjects: 978
Study: 25395381

Group type: EXPERIMENTAL
Intervention: Web-based educational program
Number of subjects: 9

Group type: COMPARATOR
Intervention: Text and video materials
Number of subjects: 9

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 9
Study: 23270749

Group type: EXPERIMENTAL
Intervention: Sodium polyaspartate-containing anti-stain dentifrice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard fluoride dentifrice
Number of subjects: 0
Study: 21521254

Group type: EXPERIMENTAL
Intervention: Octreotide LAR 20 mg every 28th day for 6 months
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Acute octreotide test
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Octreotide treatment
Number of subjects: 32
Study: 18644399

Group type: EXPERIMENTAL
Intervention: HYPO (hypohydrated by 2% body mass)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: HYPO
Number of subjects: 12

Group type: COMPARATOR
Intervention: EUH (euhydrated)
Number of subjects: 12
Study: 16925701

Group type: EXPERIMENTAL
Intervention: Pledget soaked in mydriatics placed in the inferior fornix for 20 min
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control eye drops (tropicamide, phenylepherine, atropine) administered as routine practice
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Pledget soaked in mydriatics
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control eye drops
Number of subjects: 56
Study: 12928052

Group type: EXPERIMENTAL
Intervention: IL-1B +3953 CT or TT genotypes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-1B +3953 CT or TT genotypes with IL-1A -889 TT genotype
Number of subjects: 0
Study: 10722780

Group type: EXPERIMENTAL
Intervention: Glutamine supplementation (GLN)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo treatment (PLA)
Number of subjects: 7
Study: 9534367

Group type: EXPERIMENTAL
Intervention: Toothbrush A
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Toothbrush B
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Toothbrush C
Number of subjects: 25
Study: 1585957

Group type: EXPERIMENTAL
Intervention: Prepaid plans
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional Medicaid
Number of subjects: 0
Study: 3979676

Group type: EXPERIMENTAL
Intervention: Cimetidine (20 mg/kg/24 h)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 29762252

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 32
Study: 27224474

Group type: EXPERIMENTAL
Intervention: CD64-guided group (antibiotics prescribed based on CD64 index)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment group (antibiotics prescribed based on experience and clinical symptoms)
Number of subjects: 0
Study: 25439711

Group type: EXPERIMENTAL
Intervention: Biopsychosocial prevention program (n=75) addressing playing-related health problems and providing postural training according to Mensendieck or Cesar methods.
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (n=75) participating in a program that stimulates a healthy physical activity level using a pedometer.
Number of subjects: 150
Study: 21979149

Group type: EXPERIMENTAL
Intervention: Approach‐Avoidance Task (AAT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (n=49)
Number of subjects: 34
Study: 19736368

Group type: EXPERIMENTAL
Intervention: Aerosolized L-epinephrine
Number of subjects: 62

Group type: COMPARATOR
Intervention: Budesonide
Number of subjects: 62
Study: 17606774

Group type: EXPERIMENTAL
Intervention: Mixed amphetamine salts extended release (MAS‐XR; Adderall)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atomoxetine (Strattera)
Number of subjects: 0
Study: 16207775

Group type: EXPERIMENTAL
Intervention: Violent video game exposure (VVE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonviolent video game exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High VVE
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mediational factors (trait hostility, empathy, hostile perceptions)
Number of subjects: 0
Study: 11854876

Group type: EXPERIMENTAL
Intervention: Heparin-bonded cardiopulmonary bypass (HB-CPB)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Nonheparin-bonded cardiopulmonary bypass (NH-CPB)
Number of subjects: 61
Study: 10407202

Group type: EXPERIMENTAL
Intervention: Face with opened eyes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Face with closed eyes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eyes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scrambled face
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hand
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MEG recording
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EEG recording
Number of subjects: 0
Study: 7566580

Group type: EXPERIMENTAL
Intervention: Intravenous calcitriol (0.045 micrograms/kg/weekly)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Intermittent oral calcitriol (0.045 micrograms/kg/weekly)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Daily oral calcitriol (0.045 micrograms/kg/weekly)
Number of subjects: 26
Study: 1981436

Group type: EXPERIMENTAL
Intervention: Topical clindamycin phosphate 1% twice daily
Number of subjects: 66

Group type: COMPARATOR
Intervention: Oral minocycline 50 mg twice daily
Number of subjects: 66
Study: 7029294

Group type: EXPERIMENTAL
Intervention: 4 drugs (vincristine, dactinomycin, cyclophosphamide, adriamycin)
Number of subjects: 251

Group type: COMPARATOR
Intervention: 3 drugs (vincristine, dactinomycin, cyclophosphamide)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: 3 drugs and bilateral pulmonary irradiation (approximately 1,500 rad in 2 weeks)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT) doses to the primary tumor
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Patients with lesions in the pelvis
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Patients with lesions in the humerus
Number of subjects: 251
Study: 30939480

Group type: EXPERIMENTAL
Intervention: Intensive treatment group (systolic blood pressure target of < 120 mm Hg)
Number of subjects: 9361

Group type: COMPARATOR
Intervention: Standard treatment group (systolic blood pressure target of < 140 mm Hg)
Number of subjects: 9361
Study: 27124589

Group type: EXPERIMENTAL
Intervention: Real-time feedback (RTF) via touch screens installed in waiting areas for 12 weeks, with practice staff encouraging participation.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Costs associated with implementing RTF in practices.
Number of subjects: 0
Study: 25919263

Group type: EXPERIMENTAL
Intervention: Active pulsed electromagnetic field therapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham pulsed electromagnetic field therapy
Number of subjects: 32